Table 2.
| |||||
---|---|---|---|---|---|
compounda | X | P. falciparum growth inhibition IC50 (nM)c | % recovery (200 μM IPP)e | PfIspD IC50 (nM)f | % E. coli growth inhibition (18 h)h |
1b | H | >10 000d | ND | >5000g | NI @ 250 μM |
1c | 2′-Cl | 3280 ± 990d | 60 ± 5 @ 10 μM | ~1000 | NI @ 250 μM |
1d | 4′-Cl | 1170 ± 60d | 50 ± 7 @ 10 μM | 510 ± 90 | NI @ 250 μM |
1e | 2′-Cl,4′-Me | 410 ± 40d | 100 @ 2.5 μM | 82 ± 10 | NI @ 500 μMc |
1f | 2′-Me,4′-Cl | 700 ± 90d | 100 @ 2.5 μM | 260 ± 50 | NI @ 500 μMc |
1g | 2′,4′-F2 | 780 ± 175d | 100 @ 5 μM | 230 ± 10 | NI @ 500 μMc |
1h | 2′-F,4′-Cl | 860 ± 80 | 100 @ 5 μM | 140 ± 30 | NI @ 250 μM |
1i | 2′-Cl,4′-F | 433 ± 55 | 100 @ 10 μM | 100 ± 10 | NI @ 250 μM |
1j | 2′-Cl,4′-Br | 320 ± 60 | 100 @ 5 μM | 34 ± 11 | NI @ 250 μM |
1k | 2′-Br,4′-Cl | 360 ± 40 | 100 @ 5 μM | 31 ± 4 | NI @ 125 μM |
1l | 2′,4′-Br2 | 590 ± 20 | 100 @ 10 μM | 84 ± 14 | NI @ 125 μM |
1m | 2′-I,4′-F | 970 ± 180 | 100 @ 10 μM | 140 ± 70 | NI @ 250 μM |
1n | 2′-F,4′-I | 3343 ± 496 | 100 @ 10 μM | 130 ± 20 | NI @ 125 μM |
1o | 2′-Br,4′-I | 1500 ± 200 | 80 ± 5 @ 10 μM | ND | ND |
1p | 2′-Cl,4′-OMe | >5000 | ND | ND | ND |
1q | 2′-OMe,4′-Cl | 2500 ± 600 | ND | ND | ND |
1rb | 2′-Cl,4′-OH | >5000 | ND | ND | ND |
1s | 2′-Cl,4′-CO2H | NI @ 10 000 | ND | ND | ND |
1t | 2′,4′-(CF3)2 | >10 000d | ND | >5000g | NI @ 250 μM |
1u | 2′,4′-Me2 | 70% inh. @ 10 000d | ND | ~1000 | NI @ 250 μM |
1v | 2′,4′-(OMe)2 | >20 000d | ND | >5000g | NI @ 250 μM |
1w | 3′,4′-Cl2 | >10 000 | ND | NI @ 500 nM | NI @ 250 μM |
1x | 3′,4′-(OMe)2 | >20 000d | ND | ND | ND |
1y | 2′,6′-F2,4′-Cl | 1800 ± 150 | 80 ± 8 @ 10 μM | ND | ND |
1z | 2′,3′,4′-F3 | ~20 000 | ND | ND | ND |
1aa | 2′-Br,4′-F,5′-OMe | >10 000 | ND | ND | ND |
1ab | NA | >10 000 | ND | ND | ND |
1ac | NA | >5000 | ND | ND | ND |
1ad | NA | >10 000 | ND | ND | ND |
1ae | NA | >10 000 | ND | ND | ND |
1af | NA | >5000 | ND | ND | ND |
All compounds are trans-configured and derived from (S)-Trp-OMe; all are (1R,3S) except for 1ac, which is (1S,3S) due to a Cahn-Ingold-Prelog priority switch.
This compound was tested as an approximate 1:1 mixture of the (1R,3S) and (1S,3S)-stereoisomers.
MRA-150, chloroquine-resistant (intermediate), pyrimethamine-resistant, mefloquine-resistant.
Data reported previously.13
Drug at indicated concentration.
Recombinant P. falciparum IspD IC50 values measured at 60 nM Pf IspD.
Approximately 10% inhibition at 1000 nM.
NA signifies “not applicable”. NI signifies “no inhibition”. ND signifies “not determined”. Values represent averages of at least two independent assays ± SEM.